BLRX BioLineRx Ltd

P/E --
Forward P/E 93.46
Price/Sales 7.92
Beta 0.702
Div Yield --
Market Cap --

Company Analysis

Latest News

🟢 BioLineRx is trading 6.7% up

BioLineRx is trading at $2.17, up 6.70%, with no October 22 company-specific catalyst identified. - BioLineRx’s investor-relations press-release page lists an...

🔴 BioLineRx is trading 5% down with no company-specific catalyst identified

BioLineRx is trading at $2.02 (-5.16%), with no specific cause established for the decline. - No new company-specific announcement was identified for October...

🟢 BioLineRx is trading 5% up on October 20, 2026, as biotech ETF XBI rises

BioLineRx is trading at $2.12, up 5.20%, amid broader biotech-sector strength, with XBI up 2.10% during the regular session. - No new company-specific...

🟢 BioLineRx is trading 7.5% up today as no company-specific catalyst is confirmed

BioLineRx is trading at $2.16, up 7.46%, with no confirmed company-specific catalyst identified for the October 19 move. - The latest release on the company’s...

🟢 BioLineRx is trading 5% up in pre-market with no confirmed company-specific catalyst

BioLineRx is trading at $2.12, up 5.47%, with no confirmed company-specific catalyst identified for the October 19 pre-market move. - BioLineRx’s...

🟢 BioLineRx is trading 12.2% up with no confirmed catalyst identified

BioLineRx is trading 12.2% up at $2.30, with no confirmed catalyst identified for the October 16, 2026 move. - The company's investor-relations page lists...

🟢 BioLineRx is trading 6.1% up

BioLineRx is trading 6.13% up at $2.17 on October 15, 2026; the specific catalyst for the gain remains unclear. - No new company-specific announcement...

🔴 BioLineRx is trading 6.5% down today amid broader market pressure from hotter-than-expected inflation

BioLineRx is trading 6.51% lower at $2.01, with broader market weakness the likeliest available context, though no stock-specific cause is confirmed. - No new...

🟢 BioLineRx is trading 5% up in pre-market — no confirmed overnight catalyst

BioLineRx is trading 5.07% higher at $2.28 before the October 13, 2026 open, versus its October 12 close of $2.17; no confirmed overnight catalyst was...

🔴 BioLineRx is trading 5.4% down in pre-market

BioLineRx is trading 5.4% down at $2.12 before the October 12, 2026 market open; no clear company-specific announcement explaining the decline surfaced in...

🟢 BioLineRx is trading 6.8% up in pre-market

BioLineRx is trading at $2.36, up 6.79% before the October 8, 2026, market open; the reason for the move remains unclear. - No clear company-specific...

🔴 BioLineRx is trading 6.4% down amid broader biotech weakness and risk-off pressure

BioLineRx is trading 6.38% down at $2.19 on October 7, 2026, consistent with broader biotech weakness and risk-off pressure rather than a confirmed...

🟢 BioLineRx is trading 7% up in pre-market with no new company-specific announcement found

BioLineRx is trading $2.51, up 6.81%, with no new company-specific announcement found to explain the October 1 pre-market rise. - BioLineRx’s...

🔴 BioLineRx is trading 6% down in after-hours trading

BioLineRx is trading 5.96% lower at $2.21 after hours, extending a weak stretch without a clear company-specific catalyst. - Shares closed at $2.35 in the...

🔴 BioLineRx is trading 5.8% down amid broader market weakness

BioLineRx is trading at $2.44, down 5.79%, in a risk-off session amid geopolitical tensions and rising oil prices; broader market weakness may contribute but...

🟢 BioLineRx is trading 6.28% up today; catalyst remains uncertain

BioLineRx is trading at $2.57, up +6.28%, with the catalyst uncertain. - No clear company-specific announcement was identified for September 23, 2026. - The...

🟢 BioLineRx is trading 5.37% up in pre-market amid a 2.61% biotech pre-market gain

BioLineRx is trading at $2.55, up 5.37%, with the broader biotech sector’s 2.61% pre-market gain the strongest available explanation for the move. - No clear...

🟢 BioLineRx is trading 9.8% up in pre-market

BioLineRx is trading +9.80% at $2.80 after no clear company-specific catalyst was identified for September 10, 2026. - The latest available company update...

🔴 BioLineRx is trading 9.02% down in after-hours trading with no new company-specific catalyst identified

BioLineRx is trading 9.02% down at $2.32 after-hours on September 9, 2026, versus the regular-session close of $2.55; no major company announcement, earnings...

🔴 BioLineRx is trading 5.98% down in after-hours trading after Q2 net loss widened

BioLineRx is trading 5.98% down now at $2.51 after investors continued digesting its August 31, 2026, second-quarter results. - Revenue was $0.3 million,...